DexCom (DXCM) drew fresh attention after reporting second quarter 2026 results with higher sales and earnings, and raised full year revenue guidance to a range of about US$5.18b to US$5.25b.

DexCom shares have moved sharply higher in recent weeks, with a 7 day share price return of 16.15% and a 90 day share price return of 44.04%. The 1 year total shareholder return of 15.21% contrasts with weaker 3 and 5 year total shareholder returns. This suggests recent momentum has picked up after a tougher multi year period as investors react to raised guidance, product updates, and the Nutrisense acquisition.

If DexCom’s recent move has your attention, this can be a good moment to see what else is gaining traction in healthcare technology using the 41 healthcare AI stocks

After DexCom’s sharp rebound, the stock now sits only modestly below analyst targets while still trading at a sizeable discount to some intrinsic value estimates. Does that spread point to remaining upside or to a market that is already catching up?

Most Popular Narrative: 5.1% Undervalued

The most followed DexCom narrative pegs fair value at $91.64, slightly above the last close at $86.94, and builds a case around reimbursement and earnings power.

The recent expansion of insurance reimbursement for type 2 non-insulin diabetes patients now covering nearly 6 million lives across the three largest U.S. PBMs opens a large, previously untapped segment of DexCom's addressable market, driving new patient growth and supporting robust multi-year revenue expansion.

Growing global recognition of CGM efficacy, with recent clinical trial evidence and expanded coverage in international markets (e.g., France, Japan, and Ontario, Canada), positions DexCom to penetrate underpenetrated regions and diversify revenue streams, creating sustainable top-line growth.

Curious what sits behind that fair value gap for DexCom? The narrative focuses on steady top line growth, higher margins and a future earnings multiple that is lower than today's level. The exact mix of growth, profitability and discount rate assumptions might surprise you.

Result: Fair Value of $91.64 (UNDERVALUED)

However, DexCom’s story can change quickly if Medicare pricing pressure from potential CMS competitive bidding bites harder than expected or if CGM competition erodes its core type 1 base.

Another View On DexCom’s Valuation

While the Simply Wall St fair value framework suggests DexCom is trading about 32.7% below intrinsic value based on future cash flows, the current 32.8x P/E is slightly above the US Medical Equipment industry at 31.9x and above the peer average of 26.7x. It also sits just above a 32.4x fair ratio. That mix of discount to intrinsic value and premium to earnings peers raises a simple question: Is the opportunity in DexCom’s cash generation, or in waiting for a better entry point on earnings?

Next Steps

If this mix of optimism and caution on DexCom still leaves you undecided, act while the data is fresh and pressure test the upside yourself with the 3 key rewards.

Looking for more investment ideas beyond DexCom?

If DexCom has you thinking more broadly about opportunities, do not stop here. Use the Simply Wall St Screener to spot other stocks that might fit your approach.

• Target dependable income by reviewing companies in the 7 dividend fortresses.
• Hunt for quality at a compelling price through the 52 high quality undervalued stocks.
• Prioritize sleep-at-night resilience by checking stocks in the 82 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.